Business Wire

Agendia to Showcase Robust Clinical Research at SABCS 2020 Emphasizing Need for Diversity of Data to Treat Breast Cancer Patients

Share

Agendia, Inc., a world leader in precision oncology for breast cancer, announced today that it will present new data from ongoing clinical research evaluating the MammaPrint® and BluePrint® genomic tests at the upcoming 2020 San Antonio Breast Cancer Symposium (SABCS 2020), taking place virtually December 8-11, 2020.

These data, which build upon existing clinical research that demonstrates the efficacy of MammaPrint and BluePrint testing to consistently inform optimal treatment planning, highlight Agendia’s many trials in progress that will ultimately impact patient treatment and outcomes.

Specific data selected for poster spotlight discussions include:

  • BluePrint performance in predicting pertuzumab benefit in genomically HER2-positive patients: a biomarker analysis of the APHINITY trial
    Authors: Krop, I., et al.
    Session: Spotlight Poster Discussion 3 | Wednesday, December 9, 2020 | 6:30pm – 7:30pm CST
    Poster #: PD3-01
  • 5-year outcomes in the NBRST trial: Preoperative MammaPrint and BluePrint breast cancer subtype is associated with neoadjuvant treatment response and survival
    Authors: Whitworth, P., et al.
    Session: Spotlight Poster Discussion 9 | Thursday, December 10, 2020 | 3:30pm – 4:45pm CST
    Poster #: PD9-01

In addition, Laura van’t Veer, PhD, co-founder and Chief Research Officer at Agendia, will be giving an oral presentation on an abstract entitled “How low is low risk: MINDACT updated outcome and treatment benefit in patients considered clinical low risk and stratified by genomic signature, age and nodal status.”

“The MammaPrint and BluePrint assays give patients with breast cancer and their healthcare providers the precise information they need to determine which treatment approach is the most targeted and effective for their situation,” says William Audeh, MD, MS, Chief Medical Officer at Agendia. “Our continued efforts to identify and understand the biologic drivers of breast cancer in large patient populations have also enabled us to look within these to study unique subsets of people, and to offer additional important insights, as we continue to expand knowledge in breast cancer and build a library of data that will be of benefit to patients.”

Following are details of additional Agendia abstracts that have been accepted for SABCS 2020:

  • How low is low risk: MINDACT updated outcome and treatment benefit in patients considered clinical low risk and stratified by genomic signature, age and nodal status
    Authors: van’t Veer, L.J., et al.
    Session: General Session 4 | Friday, December 11, 2020 | 8:45am – 11:30am CST
    Poster #: PS6-01
    Presentation #: Oral Presentation GS4-11 | Presentation 11:15am-11:25am CST | Live Q&A Session 11:25am-11:30am CST
  • Molecular subtyping by BluePrint improves prediction of treatment responses and survival outcomes in patients with discordant clinical and genomic classification
    Authors: Whitworth, P., et al.
    Session: Poster Session 4
    Poster #: PS4-04
  • The 70-gene signature (MammaPrint) accurately predicts distant breast cancer recurrence risk in patients aged ≥70 years from the population-based observational FOCUS cohort.
    Authors: Noordhoek, I., et al.
    Session: Poster Session 6
    Poster #: PS6-06
  • Comparing MammaPrint and BluePrint results between core needle biopsy and surgical resection breast cancer specimens
    Authors: McKelley, J., et al.
    Session: Poster Session 6
    Poster #: PS6-19
  • MammaPrint and BluePrint as prognostic indicators for elderly patients with early stage breast cancer
    Authors: Blumencranz, P.W., et al.
    Session: Poster Session 6
    Poster #: PS6-41
  • Racial disparities within Basal-type breast cancer: clinical and molecular features of African American and Caucasian obese patients
    Authors: Sharma, D., et al.
    Session: Poster Session 7
    Poster #: PS7-68
  • Molecular profiles and clinical-pathological features of Asian early-stage breast cancer patients
    Authors: Chen, M., et al.
    Session: Poster Session 7
    Poster #: PS7-69
  • Differential gene expression analysis and clinical utility of MammaPrint and BluePrint in male breast cancer patients
    Authors: Crozier, J., et al.
    Session: Poster Session 14
    Poster #: PS14-11
  • Differential gene expression in Luminal-type invasive lobular carcinoma and invasive ductal carcinoma by MammaPrint risk stratification
    Authors: Lesnikoski, B., et al.
    Session: Poster Session 18
    Poster #: PS18-03
  • Using BluePrint to elucidate the molecular heterogeneity of triple negative breast cancers
    Authors: Kaklamani, V.G., et al.
    Session: Poster Session 18
    Poster #: PS18-05
  • The FLEX real-world data platform explores new gene expression profiles and investigator-initiated protocols in early stage breast cancer
    Authors: Lee, L., et al.
    Session: Ongoing Trials Posters
    Poster #: OT-12-01

These data underscore Agendia’s mission to help guide the diagnosis and personalized treatment of breast cancer for all patients throughout their treatment journey.

Please follow us on our Twitter, Facebook and LinkedIn pages for unique content we will be sharing throughout SABCS.

About Agendia

Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing early stage breast cancer patients and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient.

MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings.

By developing evidence-based novel genomic tests and conducting groundbreaking research while building an arsenal of data that will help treat breast cancer, Agendia aims to improve patient outcomes and support the evolving clinical needs of breast cancer patients and their physicians every step of the way, from initial diagnosis to cancer-free.

Agendia’s assays can be ordered on core biopsies or surgical specimens with results in as little as 5-7 days to inform pre- and post-operative treatment decisions. For more information on our assays and our ongoing trials, please visit www.agendia.com.

Contact information

Terri Clevenger
Westwicke/ICR Healthcare PR
Tel: 203.856.4326
Terri.Clevenger@icrinc.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary Endpoint4.12.2020 14:00:00 EETPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced top-line results from the Phase 3 clinical trial evaluating the efficacy and safety of the investigational drug TAK-620 (maribavir), in the treatment of transplant recipients with refractory/resistant cytomegalovirus (CMV) infection. The TAK-620-303 (SOLSTICE) trial (NCT02931539) is a multicenter, randomized, open-label, active-controlled trial comparing eight weeks of treatment with either maribavir or investigator assigned treatment (IAT) in transplant recipients with CMV infection refractory or resistant to existing antiviral treatments (i.e., one or a combination of ganciclovir, valganciclovir, foscarnet or cidofovir). The SOLSTICE trial met its primary endpoint, defined as the proportion of patients who achieved confirmed CMV viremia clearance compared to IAT at the end of Study week 8. In addition, the SOLSTICE trial met its key secondary endpoint, defined as achievement of CMV viremia clearance

Janssen Submits Marketing Authorisation Extension to the European Medicines Agency to Register Paliperidone Palmitate 6-Monthly (PP6M) for Treatment of Schizophrenia in Adults4.12.2020 12:01:00 EETPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson submitted a Marketing Authorisation Extension Application to the European Medicines Agency (EMA) to register paliperidone palmitate 6-monthly (PP6M) for the maintenance treatment of schizophrenia in adult patients who are clinically stable on paliperidone palmitate 1‑monthly (PP1M)1 or 3-monthly (PP3M)2 injectable products. If approved, this long‑acting injectable will provide adults living with schizophrenia a twice-yearly dosing regimen, the longest dosing interval available for an antipsychotic medication in the European Economic Area.3 “Janssen’s roots in neuroscience began with research and development of novel therapeutic options for schizophrenia, and this filing builds on that 60-year commitment,” said Bill Martin, Global Therapeutic Area Head, Neuroscience, Janssen Research & Development, LLC. “We designed this unique dosing regimen so people with schizophrenia and their healthcare team can focus less on medication inte

Patrice Bula to be appointed as new Chairman of Froneri4.12.2020 11:30:00 EETPress release

After more than 4 years as Chairman of Froneri, Luis Cantarell has expressed his desire to step down at the end of December 2020. Luis’s strategic vision, in-depth knowledge of the Ice Cream business as well as his energizing and inspirational leadership were decisive factors in the forming and ensuing success of Froneri, a joint-venture partnership between Nestlé and PAI Partners created in September 2016. Under Luis’s leadership, Froneri has achieved rapid sales and profit growth, steadily gaining market shares. With presence in 23 markets, a portfolio of iconic brands and an exceptional management team, Froneri is now well-placed to achieve global leadership in the Ice Cream category. To replace Luis, we are pleased to announce the nomination of Patrice Bula, currently Executive Vice President at Nestlé and a Supervisory Board Member of Froneri, and this since its creation. With a rich career spanning more than 40 years with Nestlé SA, of which the last 10 as Executive Vice Presiden

Xlife Sciences AG: Successful Capital Raising of Six Million Swiss Francs4.12.2020 11:00:00 EETPress release

Capital increase of Xlife Sciences AG Successful capital raising of six million Swiss francs Xlife Sciences AG has successfully closed its capital increase and raised a total of 6.02 million Swiss Francs of new capital as of December 3, 2020. The placement was oversubscribed at the end of the subscription period. The management of the company sees the strong demand as a confirmation for its business model. The capital will be used almost exclusively for existing and new projects. In the capital round completed on December 3, 2020, existing and new investors subscribed for shares with a total value of CHF 6.02 million. For Oliver R. Baumann, CEO of Xlife Sciences AG, the high demand of investors is a confirmation of the successful business model. "The strong interest of investors shows that our company, with its strategy of holding and developing a broad portfolio of early-stage life science projects is an attractive investment even in challenging times such as the corona crisis". Inves

Rand Technology Appoints Key Executives Across Global Regions4.12.2020 02:30:00 EETPress release

Rand Technology (Rand) has appointed Kim Fix, Chief Operating Officer (COO), Americas & Europe; Frederick Fu, President and Managing Director, Asia-Pacific (APAC); Nami Mokri, Vice President, Sales & Sourcing, APAC; Kevin Sheehan, Chief Information Officer (CIO); and Jennifer Strawn, Director, Sourcing & Procurement, Americas & Europe. Kim Fix, Global Vice President, QA & Operations, has been appointed to COO, Americas & Europe. Kim will lead Rand’s sales and sourcing teams’ operations across the Americas and Europe and oversee global compliance, quality assurance, and operations. Kim has been integral to Rand’s preferred status with its business partners and multi-site ISO, OHSAS, ANSI ESD, and R2 certifications. Frederick Fu joined Rand as President and Managing Director, APAC. He previously served as Avnet’s President of APAC. He has been fundamental to Rand’s efficacy, growth, strategy, and success in the APAC region. Nami Mokri was appointed Vice President, Sales & Sourcing, APAC.

Kalray Joins MLCommons as Founding Member3.12.2020 20:30:00 EETPress release

Kalray (Euronext Growth Paris: FR0010722819 – ALKAL) (Paris:ALKAL), a pioneer in processors for new intelligent systems, today announced it has joined MLCommons as founding member. MLCommons is a not for profit, engineering consortium founded by 30+ global technology and academic leaders in AI and Machine Learning to accelerate machine learning innovation and broaden access to this critical technology for the public good. Initially formed as MLPerf, MLCommons boasts a founding board that includes representatives from Alibaba, Facebook AI, Google, Intel, NVIDIA and Professor Vijay Janapa Reddi of Harvard University with the objective to deliver industry-wide benchmarks, best practices and datasets to speed computer vision, natural language processing, and speech recognition development for all. “MLCommons has a clear mission - accelerate Machine Learning innovation to ‘raise all boats’ and increase its positive impact on society” said Peter Mattson, President of MLCommons. “We are excit

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom